MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-09-2025
Tilray Revenue 2011-2026 | TLRY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 627 M | 628 M | 513 M | 405 M | 237 M | 36.9 M | 20.4 M | 8.43 M | 551 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 628 M | 551 K | 275 M |
Quarterly Revenue Tilray
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 210 M | - | 186 M | 211 M | 200 M | - | 188 M | 194 M | 177 M | - | 146 M | 144 M | 153 M | 297 M | 152 M | 155 M | 168 M | 323 M | 124 M | 129 M | 117 M | -1.33 M | -1.75 M | 46.9 M | 51.1 M | 45.9 M | 23 M | 15.5 M | 10 M | 9.74 M | 7.81 M | 5.11 M | 5.41 M | 4.99 M | 5.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 323 M | -1.75 M | 109 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.14 | -1.72 % | $ 123 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
651 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.63 | 0.19 % | $ 1.38 B | Canada |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 4.22 | -0.94 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 12.36 | 1.64 % | $ 633 M | USA |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | $ 21.55 | 0.05 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
266 M | $ 6.65 | -0.3 % | $ 412 M | USA |
 |
Harrow Health
HROW
|
130 M | $ 49.0 | -2.04 % | $ 1.6 B | USA |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 1.21 | -9.02 % | $ 21.1 M |  China |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.68 | -1.18 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 6.95 | -0.57 % | $ 2.54 B | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 5.18 | - | $ 682 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 25.88 | -0.73 % | $ 1.2 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 3.98 | 0.51 % | $ 56 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
920 M | $ 1.66 | 0.61 % | $ 3.37 M | Canada |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 0.83 | 2.18 % | $ 19.4 M | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
4.37 B | $ 13.92 | -0.14 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
123 M | $ 0.45 | -1.28 % | $ 7.13 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.83 | 6.62 % | $ 145 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 3.64 | 0.64 % | $ 4.52 M | USA |
 |
Assertio Holdings
ASRT
|
152 M | $ 9.07 | -1.41 % | $ 644 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
140 M | $ 0.63 | 4.43 % | $ 30.1 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.14 | -1.38 % | $ 289 M | USA |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 1.63 | -0.61 % | $ 17 M | USA |
 |
Viatris
VTRS
|
16.3 B | $ 12.45 | -0.72 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 1.35 | -0.37 % | $ 5.82 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |